CervoMed Inc. (CRVO)
| Market Cap | 80.41M |
| Revenue (ttm) | 6.16M |
| Net Income (ttm) | -25.58M |
| Shares Out | 9.25M |
| EPS (ttm) | -2.87 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 56,827 |
| Open | 9.21 |
| Previous Close | 9.06 |
| Day's Range | 8.64 - 9.22 |
| 52-Week Range | 1.80 - 16.94 |
| Beta | -6.48 |
| Analysts | Strong Buy |
| Price Target | 21.50 (+147.41%) |
| Earnings Date | Nov 10, 2025 |
About CRVO
CervoMed Inc., a a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in DLB and certain other major neurological disorders. It is being evaluated in a Phase 2b ... [Read more]
Financial Performance
In 2024, CervoMed's revenue was $9.74 million, an increase of 36.29% compared to the previous year's $7.14 million. Losses were -$16.29 million, 650.1% more than in 2023.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for CRVO stock is "Strong Buy." The 12-month stock price target is $21.5, which is an increase of 147.41% from the latest price.
News
CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy Bodies
Phase 2b trial showed significant improvements on primary and key secondary outcomes measures, most prominently in patients without AD co-pathology
CervoMed Presents New Plasma Biomarker Data That Indicates Neflamapimod Broadly Improves Neuroinflammation and Neurodegeneration in Dementia with Lewy Bodies (DLB)
1st of two presentations with results from Phase 2b study of neflamapimod at the 18 th Clinical Trials on Alzheimer's Disease (CTAD) Conference
CervoMed to Share New Data on Neflamapimod as a Treatment for Dementia with Lewy Bodies at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference
Late-breaking oral presentation by a leading global authority in Dementia with Lewy bodies (DLB) to highlight updated data from Phase 2b study on neflamapimod treatment for DLB
CervoMed to Present at the Emerging Growth Conference
BOSTON, Oct. 20, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today ...
CervoMed Drug Cut Dementia Progression Risk By 75% In Trial
CervoMed Inc. (NASDAQ:CRVO) on Wednesday shared additional data from its Phase 2b RewinD-LB trial of neflamapimod for dementia with Lewy bodies (DLB).
CervoMed Announces New Data from Phase 2b Trial Demonstrating Neflamapimod's Potential as a Treatment for Dementia with Lewy Bodies
Significant improvement relative to placebo on primary outcome measure, change in Clinical Dementia Rating Sum of Boxes (CDR-SB), demonstrated in a within-subject analysis in participants with low lik...
CervoMed to Participate in the 4th Annual ROTH Healthcare Opportunities Conference
BOSTON, Oct. 02, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today ...
CervoMed Highlights Neflamapimod's Potential Benefits in Session on Dementia with Lewy Bodies at the 150th Annual American Neurology Association Conference
BOSTON, Sept. 17, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today...
CervoMed to Participate in Upcoming Investor Conferences
BOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that Company ma...
CervoMed's Dementia Data Show Slowed Disease Progression
CervoMed Inc. CRVO on Monday shared 32-week data from the Extension phase of its Phase 2b RewinD-LB trial evaluating oral neflamapimod in patients with Dementia with Lewy Bodies (DLB).
CervoMed Announces 32-Week Data from RewinD-LB Trial Extension Phase Showing Neflamapimod's Sustained Effect on Slowing Clinical Progression in Patients with Dementia with Lewy Bodies and Associated Reduction in a Key Plasma Biomarker of Neurodegeneration
Based on the primary endpoint of Clinical Dementia Rating Sum of Boxes (CDR-SB), patients treated with neflamapimod showed 54% risk reduction in clinically significant worsening compared to control at...
CervoMed Announces Late-Breaking Presentations at Alzheimer's Association® International Congress 2025
BOSTON, July 08, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced it will deliver ...
CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates
Reported positive 16-week results from the extension phase of the Phase 2b RewinD-LB trial, demonstrating proof-of-concept for neflamapimod as a potential treatment for dementia with Lewy bodies (DLB)
Biotech Stocks Q1 2025 Recap: Winners And Underperformers
Investing in biotech can be highly rewarding but is fraught with risks; understanding past catalysts can help investors make informed decisions and minimize downside risk. CervoMed Inc. surged over 30...
CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurologic Disorders (AP/PD™)
BOSTON, March 25, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced it will deliver...
CervoMed: Extension Study Data In Dementia With Lewy Bodies Is Potentially Exciting, With Caveats
CervoMed's stock surged more than 400% after interim data showed significant improvement with a new batch of neflamapimod in treating Dementia with Lewy Bodies. The recent interim readout deserves exc...
CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies
A new batch of neflamapimod capsules led to increased plasma drug concentrations and demonstrated improvement (p
CervoMed to Present at the 8th International Lewy Body Dementia Conference
BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that topline res...
CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Dec. 12, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO) (the “Company”), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced ...
CervoMed's Dementia Candidate Fails In Mid-Stage Study, Stock Plummets
On Tuesday, CervoMed Inc. CRVO stock is trading lower after the company revealed topline data from the RewinD-LB Phase 2b clinical trial evaluating neflamapimod for dementia with Lewy bodies (DLB).
CervoMed's stock craters 77% after failed trial of treatment for rare brain disease
CervoMed Inc.'s stock cratered early Tuesday after the biotech company said a midstage trial of a treatment for patients with dementia with Lewy bodies, or DLB, failed to meet its main goals.
CervoMed's dementia drug fails to meet mid-stage trial goals
U.S. drug developer CervoMed said on Tuesday its experimental drug for a common degenerative brain disease did not meet the main or secondary goals in a mid-stage clinical trial.
CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies
—Neflamapimod did not demonstrate statistically significant effects versus placebo on primary and secondary endpoints at 16 weeks—
CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia
Designation underscores significant unmet need in frontotemporal dementia and the potential role of neflamapimod in multiple neurologic disorders
CervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
- Reported last patient, last visit in its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with early-stage dementia with Lewy bodies (DLB) in October 2024; topline data expected...